DOCSLIB.ORG

Pg 1 of 189 Products and Pricing on the Alberta Blue Cross Drug Price List (ABCDPL) Effective April 13, 2017

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Products and Pricing on the Alberta Blue Cross Drug Price List (ABCDPL) Effective April 13, 2017 DIN/ PIN/ NPN Product Description Route Form MFR Unit of Issue Base Price 00002192691 3TC 10 MG/ML ORAL LIQUID ORL LIQ GSK ML 0.3307 00002192683 3TC 150 MG TABLET ORL TAB GSK TAB 5.0507 00002247825 3TC 300 MG TABLET ORL TAB GSK TAB 9.8070 00002162113 5 BENZAGEL 5% TOPICAL (ALCOHOL) GEL TOP ALCGEL CLC G 0.2080 00002166607 5 BENZAGEL 5% TOPICAL LOTION TOP LOT NVC ML 0.1984 00000437999 5% DEXTROSE & 0.45% NACL W 0.15% KCL 20 MEQ INJ INJ DEFAUL BAX ML 0.0030 00000037974 50% DEXTROSE 500 MG/ML INJECTION USP INJ DEFAUL HSP ML 0.5842 00080013172 5-HTP 100 MG CAPSULE ORL CAP VTH CAP 0.2000 00002414570 ABBOTT-CITALOPRAM 10 MG TABLET ORL TAB ABB TAB 0.1432 00002414589 ABBOTT-CITALOPRAM 20 MG TABLET ORL TAB ABB TAB 0.2397 00002414597 ABBOTT-CITALOPRAM 40 MG TABLET ORL TAB ABB TAB 0.2397 00002412942 ABBOTT-CLOPIDOGREL 75 MG TABLET ORL TAB ABB TAB 0.4735 00002414805 ABBOTT-LEVETIRACETAM 250 MG TABLET ORL TAB ABB TAB 0.8000 00002414791 ABBOTT-LEVETIRACETAM 500 MG TABLET ORL TAB ABB TAB 0.9750 00002414783 ABBOTT-LEVETIRACETAM 750 MG TABLET ORL TAB ABB TAB 1.3500 00002414546 ABBOTT-OLANZAPINE ODT 10 MG TABLET ORL DISNTAB ABB TAB 1.2857 00002414538 ABBOTT-OLANZAPINE ODT 5 MG TABLET ORL DISNTAB ABB TAB 0.6434 00002412969 ABBOTT-PANTOPRAZOLE 40 MG ENTERIC-COATED TABLET ORL ECT ABB TAB 0.3628 00002412985 ABBOTT-QUETIAPINE 100 MG TABLET ORL TAB ABB TAB 0.3295 00002412993 ABBOTT-QUETIAPINE 200 MG TABLET ORL TAB ABB TAB 0.6617 00002412977 ABBOTT-QUETIAPINE 25 MG TABLET ORL TAB ABB TAB 0.1235 00002413000 ABBOTT-QUETIAPINE 300 MG TABLET ORL TAB ABB TAB 0.9656 00002422638 ABBOTT-RABEPRAZOLE 10 MG ENTERIC-COATED TABLET ORL ECT ABB TAB 0.1204 00002422646 ABBOTT-RABEPRAZOLE 20 MG ENTERIC-COATED TABLET ORL ECT ABB TAB 0.2408 00002414619 ABBOTT-TOPIRAMATE 100 MG TABLET ORL TAB ABB TAB 0.5928 This document is for pricing use only and should not be used to determine benefit status information. Pricing is applicable to a Drug Product regardless of the package size for each Drug Product. Pg 1 of 189 Products and Pricing on the Alberta Blue Cross Drug Price List (ABCDPL) Effective April 13, 2017 DIN/ PIN/ NPN Product Description Route Form MFR Unit of Issue Base Price 00002414627 ABBOTT-TOPIRAMATE 200 MG TABLET ORL TAB ABB TAB 0.8853 00002414600 ABBOTT-TOPIRAMATE 25 MG TABLET ORL TAB ABB TAB 0.3128 00002231590 ABELCET 5MG/ML LIPID COMPLEX INJECTION INJ DEFAUL SGM ML 9.4395 00001919385 ABENOL 120 MG RECTAL SUPPOSITORY RT SUP PPH SUP 0.5417 00001919393 ABENOL 325 MG RECTAL SUPPOSITORY RT SUP PPH SUP 0.6692 00001919407 ABENOL 650 MG RECTAL SUPPOSITORY RT SUP PPH SUP 0.7683 00002281066 ABRAXANE 100 MG/VIAL INJECTION INJ DEFAUL CLG VIAL 971.0000 00002245677 ABREVA 10% TOPICAL CREAM TOP CRM GKC G 7.2800 00002364174 ABSTRAL 100 MCG SUBLINGUAL TABLET SLG SLT PAL TAB 11.1930 00002364182 ABSTRAL 200 MCG SUBLINGUAL TABLET SLG SLT PAL TAB 12.6710 00002364190 ABSTRAL 300 MCG SUBLINGUAL TABLET SLG SLT PAL TAB 15.1950 00002364204 ABSTRAL 400 MCG SUBLINGUAL TABLET SLG SLT PAL TAB 17.2650 00002364212 ABSTRAL 600 MCG SUBLINGUAL TABLET SLG SLT PAL TAB 23.0300 00002364220 ABSTRAL 800 MCG SUBLINGUAL TABLET SLG SLT PAL TAB 28.7840 00001922246 AC & C 8 MG TABLET ORL TAB PPH TAB 0.0510 00002401126 ACCEL-ALENDRONATE 10 MG TABLET ORL TAB ACP TAB 0.3989 00002401134 ACCEL-ALENDRONATE 70 MG TABLET ORL TAB ACP TAB 1.9000 00002341107 ACCEL-AMLODIPINE 10 MG TABLET ORL TAB ACP TAB 0.3587 00002341093 ACCEL-AMLODIPINE 5 MG TABLET ORL TAB ACP TAB 0.2417 00002419874 ACCEL-DONEPEZIL 10 MG TABLET ORL TAB ACP TAB 0.8145 00002419866 ACCEL-DONEPEZIL 5 MG TABLET ORL TAB ACP TAB 0.8145 00002400391 ACCEL-FLUOXETINE 10 MG CAPSULE ORL CAP ACP CAP 0.3300 00002400405 ACCEL-FLUOXETINE 20 MG CAPSULE ORL CAP ACP CAP 0.3300 00002400359 ACCEL-QUETIAPINE 100 MG TABLET ORL TAB ACP TAB 0.2100 00002400375 ACCEL-QUETIAPINE 200 MG TABLET ORL TAB ACP TAB 0.4300 This document is for pricing use only and should not be used to determine benefit status information. Pricing is applicable to a Drug Product regardless of the package size for each Drug Product. Pg 2 of 189 Products and Pricing on the Alberta Blue Cross Drug Price List (ABCDPL) Effective April 13, 2017 DIN/ PIN/ NPN Product Description Route Form MFR Unit of Issue Base Price 00002400340 ACCEL-QUETIAPINE 25 MG TABLET ORL TAB ACP TAB 0.0800 00002400383 ACCEL-QUETIAPINE 300 MG TABLET ORL TAB ACP TAB 0.6300 00002435349 ACCEL-TOPIRAMATE 100 MG TABLET ORL TAB ACP TAB 0.4400 00002435357 ACCEL-TOPIRAMATE 200 MG TABLET ORL TAB ACP TAB 0.6600 00002435330 ACCEL-TOPIRAMATE 25 MG TABLET ORL TAB ACP TAB 0.2300 00002164396 ACEBUTOLOL-100 100 MG TABLET ORL TAB PDL TAB 0.0787 00002164418 ACEBUTOLOL-200 200 MG TABLET ORL TAB PDL TAB 0.1177 00002164426 ACEBUTOLOL-400 400 MG TABLET ORL TAB PDL TAB 0.2466 00002230435 ACET 160 MG RECTAL SUPPOSITORY RT SUP PPH SUP 0.6242 00001999648 ACET CODEINE 30 TABLET ORL TAB PMS TAB 0.1655 00002154234 ACETAMINOPHEN 300MG/15MG CAFFEINE/8MG COD. CAPLET ORL TAB VTH TAB 0.0348 00001977415 ACETAMINOPHEN 325 MG CAPLET ORL TAB TLI TAB 0.0592 00000789801 ACETAMINOPHEN 325 MG TABLET ORL TAB TLI TAB 0.0592 00001938088 ACETAMINOPHEN 325 MG TABLET ORL TAB JPC TAB 0.0120 00000605751 ACETAMINOPHEN 325 MG TABLET ORL TAB VTH TAB 0.0272 00000374148 ACETAMINOPHEN 325 MG TABLET ORL TAB WAM TAB 0.0184 00000789798 ACETAMINOPHEN 500 MG TABLET ORL TAB TLI TAB 0.0243 00001905864 ACETAMINOPHEN 80 MG/ML ORAL DROPS ORL DPS TLI ML 0.1300 00002272482 ACETAMINOPHEN ARTHRITIS PAIN 650 MG EXT.REL TABLET ORL ERT PRI TAB 0.0755 00000706221 ACETAMINOPHEN CAFFEINE & CODEINE 8 MG TABLET ORL TAB WTR TAB 0.0258 00002028174 ACETAMINOPHEN COMPOUND WITH CODEINE CAPLET ORL TAB PPH TAB 0.0398 00001905856 ACETAMINOPHEN COMPRIME A CROQUER 80 MG ORL TAB TLI TAB 0.1000 00002255251 ACETAMINOPHEN EXT STR EASY TO SWALLOW 500 MG TAB ORL TAB PMT TAB 0.0660 00000605778 ACETAMINOPHEN EXTRA STRENGTH 500 MG TABLET ORL TAB WTR TAB 0.0306 00002285797 ACETAMINOPHEN EXTRA STRENGTH 500 MG TABLET ORL TAB VTH TAB 0.0600 This document is for pricing use only and should not be used to determine benefit status information. Pricing is applicable to a Drug Product regardless of the package size for each Drug Product. Pg 3 of 189 Products and Pricing on the Alberta Blue Cross Drug Price List (ABCDPL) Effective April 13, 2017 DIN/ PIN/ NPN Product Description Route Form MFR Unit of Issue Base Price 00002252813 ACETAMINOPHEN EXTRA STRENGTH 500 MG TABLET ORL TAB PMT TAB 0.0621 00001904132 ACETAMINOPHEN EXTRA-STRENGTH 500 MG TABLET ORL TAB TAN TAB 0.0179 00001958836 ACETAMINOPHEN ORAL SOLUTION FOR CHILDREN USP ORL SOL TLI ML 0.0296 00002143933 ACETAMINOPHEN WITH CODEINE CAPLET ORL TAB ROG TAB 0.0460 00002025337 ACETAMINOPHEN WITH CODEINE TABLET ORL TAB PMS TAB 0.0398 00002251914 ACETAMINOPHEN, CAFFEINE & 8 MG CODEINE PHOS. TAB ORL TAB PMT TAB 0.0396 00002017431 ACETAMINOPHENE 160 MGCO.CROQUABLE POUR ENFANT ORL CTB RIV TAB 0.1475 00002022214 ACETAMINOPHENE 325 MG COMPRIME ORL TAB RIV TAB 0.0114 00000382752 ACETAMINOPHENE 325 MG TABLET ORL TAB PDL TAB 0.0114 00002362228 ACETAMINOPHENE 500 MG CAPLET ORL TAB RIV TAB 0.0149 00002022222 ACETAMINOPHENE 500 MG COMPRIME ORL TAB RIV TAB 0.0149 00000386626 ACETAMINOPHENE 500 MG TABLET ORL TAB PDL TAB 0.0149 00002017458 ACETAMINOPHENE 80MGCO.CROQUABLE POUR ENFANT ORL CTB RIV TAB 0.1000 00000834319 ACETAZONE FORTE C-8 TABLET ORL TAB RPH TAB 0.4495 00000834300 ACETAZONE FORTE TABLET ORL TAB RPH TAB 0.3399 00001999656 ACET-CODEINE 60 MG TABLET ORL TAB PMS TAB 0.2640 00002300435 ACETYLCYSTEINE 20% INHALATION SOLUTION INH SOL ALV ML 1.9500 00000718831 ACETYLSALICYLIC ACID 325 MG TABLET ORL TAB PHH TAB 0.0621 00002426757 ACH-CAPECITABINE 150 MG TABLET ORL TAB AHI TAB 1.4640 00002426765 ACH-CAPECITABINE 500 MG TABLET ORL TAB AHI TAB 4.8800 00002247551 ACID REDUCER 75 MG TABLET ORL TAB PMS TAB 0.1067 00080042609 ACIDOPHILUS PROBIOTIC COMPLETE CAPSULE ORL CAP WNP CAP 0.2892 00080011789 ACIDOPHILUS WITH BIFIDUS CAPSULE ORL CAP WNP CAP 0.1082 00002439247 ACT AMPHETAMINE XR 10 MG EXTENDED-RELEASE CAPSULE ORL ERC APH CAP 2.0758 00002439255 ACT AMPHETAMINE XR 15 MG EXTENDED-RELEASE CAPSULE ORL ERC APH CAP 2.3250 This document is for pricing use only and should not be used to determine benefit status information. Pricing is applicable to a Drug Product regardless of the package size for each Drug Product. Pg 4 of 189 Products and Pricing on the Alberta Blue Cross Drug Price List (ABCDPL) Effective April 13, 2017 DIN/ PIN/ NPN Product Description Route Form MFR Unit of Issue Base Price 00002439263 ACT AMPHETAMINE XR 20 MG EXTENDED-RELEASE CAPSULE ORL ERC APH CAP 2.5743 00002439271 ACT AMPHETAMINE XR 25 MG EXTENDED-RELEASE CAPSULE ORL ERC APH CAP 2.8235 00002439298 ACT AMPHETAMINE XR 30 MG EXTENDED-RELEASE CAPSULE ORL ERC APH CAP 3.0729 00002439239 ACT AMPHETAMINE XR 5 MG EXTENDED-RELEASE CAPSULE ORL ERC APH CAP 1.8266 00002394898 ACT ANASTROZOLE 1 MG TABLET ORL TAB APH TAB 2.5459 00002374765 ACT BETAHISTINE 24 MG TABLET ORL TAB APH TAB 0.4983 00002376520 ACT CANDESARTAN 4 MG TABLET ORL TAB APH TAB 0.3400 00002244816 ACT CLOMIPRAMINE 10 MG TABLET ORL TAB APH TAB 0.1290 00002244817 ACT CLOMIPRAMINE 25 MG TABLET ORL TAB APH TAB 0.1758 00002244818 ACT CLOMIPRAMINE 50 MG TABLET ORL TAB APH TAB 0.3237 00002397145 ACT DICLO-MISO 50 MG/200 MCG ENTERIC-COATED TABLET ORL ECT APH TAB 0.4541 00002397153 ACT DICLO-MISO 75 MG/200 MCG ENTERIC-COATED TABLET ORL ECT APH TAB 0.6179 00002397625 ACT DONEPEZIL ODT 10 MG ORALLY DISINT.
Recommended publications
  • July 21, 2021

    July 21, 2021

    1 2nd Quarter 2021 Earnings Call July 21, 2021 Cautionary Note on Forward-looking Statements This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to the business, or on the Company’s ability to execute business continuity plans, as a result of the COVID-19 pandemic; economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact
  • Medication Code Key: PMCODE and Drug Name in 2007 NHHCS Cdc-Pdf

    Medication Code Key: PMCODE and Drug Name in 2007 NHHCS Cdc-Pdf

    Medication Code Key: PMCODE and Drug Name in 2007 NHHCS PMCODE Drug Name 00002 TAMIFLU 00003 DITROPAN XL II 00004 LIDODERM PATCH 00008 VIACTIV 00010 A AND D II 00013 MYCOPHENOLATE MOFETIL 00017 SIROLIMUS 00019 HAWTHORN 00027 SYNAGIS 00032 EXCEDRIN MIGRAINE 00036 MAALOX PLUS 00037 ACEON 00038 GLYSET 00039 SONATA 00042 PROTONIX 00044 PANLOR DC 00048 MOBIC 00052 SILDENAFIL CITRATE 00053 TAMSULOSIN HYDROCHLORIDE 00054 COMTAN 00058 MINERAL SUPPLEMENT 00061 BISMUTH 00071 CERTAVITE 00073 LUXIQ 00075 SAL-TROPINE 00076 TRILEPTAL 00078 AGGRENOX 00080 CARBIDOPA-LEVODOPA 00081 EXELON 00084 PREGABALIN 00085 ORAMORPH 00096 OSTEO-BIFLEX 00099 ALOCRIL 00100 A.S.A. 00101 ISOSORBIDE DINITRATE 00102 ISOSORBIDE MONONITRATE 00107 ROSIGLITAZONE MALEATE 00109 URSODIOL 00112 MEDERMA 00113 ANDROGEL 00114 DILTIA XT 00117 CRANBERRY 00123 NICOTINE 00125 AVELOX 00132 CAL-MAG 00133 CANDESARTAN Page 1 Medication Code Key: PMCODE and Drug Name in 2007 NHHCS PMCODE Drug Name 00148 PROLIXIN D 00149 D51/2 NS 00150 NICODERM CQ PATCH 00151 TUSSIN 00152 CEREZYME 00154 CHILDREN'S IBUPROFEN 00156 PROPOXACET-N 00159 KALETRA 00161 BISOPROLOL 00167 NOVOLIN N 00169 KETOROLAC TROMETHAMINE 00172 OPHTHALMIC OINTMENT 00173 ELA-MAX 00176 PREDNISOLONE ACETATE 00179 COLLOID SILVER 00184 KEPPRA 00187 OPHTHALMIC DROPS 00190 ABDEC 00191 HAPONAL 00192 SPECTRAVITE 00198 ENOXAPARIN SODIUM 00206 ACTONEL 00208 CELECOXIB 00209 GLUCOVANCE 00211 LEVALL 5.0 00213 PANTOPRAZOLE SODIUM 00217 TEMODAR 00218 CARBAMIDE PEROXIDE 00221 CHINESE HERBAL MEDS 00224 MILK AND MOLASSES ENEMA 00238 ZOLMITRIPTAN 00239
  • Cosmetic Formulation of Skin Care Products.Pdf

    Cosmetic Formulation of Skin Care Products.Pdf

    DK9685_half-series-title 4/25/06 4:34 PM Page A Cosmetic Formulation of Skin Care Products DK9685_half-series-title 4/25/06 4:34 PM Page B COSMETIC SCIENCE AND TECHNOLOGY Series Editor ERIC JUNGERMANN Jungermann Associates, Inc. Phoenix, Arizona 1. Cosmetic and Drug Preservation: Principles and Practice, edited by Jon J. Kabara 2. The Cosmetic Industry: Scientific and Regulatory Foundations, edited by Norman F. Estrin 3. Cosmetic Product Testing: A Modern Psychophysical Approach, Howard R. Moskowitz 4. Cosmetic Analysis: Selective Methods and Techniques, edited by P. Boré 5. Cosmetic Safety: A Primer for Cosmetic Scientists, edited by James H. Whittam 6. Oral Hygiene Products and Practice, Morton Pader 7. Antiperspirants and Deodorants, edited by Karl Laden and Carl B. Felger 8. Clinical Safety and Efficacy Testing of Cosmetics, edited by William C. Waggoner 9. Methods for Cutaneous Investigation, edited by Robert L. Rietschel and Thomas S. Spencer 10. Sunscreens: Development, Evaluation, and Regulatory Aspects, edited by Nicholas J. Lowe and Nadim A. Shaath 11. Glycerine: A Key Cosmetic Ingredient, edited by Eric Jungermann and Norman O. V. Sonntag 12. Handbook of Cosmetic Microbiology, Donald S. Orth 13. Rheological Properties of Cosmetics and Toiletries, edited by Dennis Laba 14. Consumer Testing and Evaluation of Personal Care Products, Howard R. Moskowitz 15. Sunscreens: Development, Evaluation, and Regulatory Aspects. Second Edition, Revised and Expanded, edited by Nicholas J. Lowe, Nadim A. Shaath, and Madhu A. Pathak DK9685_half-series-title 4/25/06 4:34 PM Page C 16. Preservative-Free and Self-Preserving Cosmetics and Drugs: Principles and Practice, edited by Jon J.
  • Propylene Glycol

    Propylene Glycol

    PROPYLENE GLYCOL Your patch test result indicates that you have a contact allergy to propylene glycol. This contact allergy may cause your skin to react when it is exposed to this substance although it may take several days for the symptoms to appear. Typical symptoms include redness, swelling, itching, and fluid-filled blisters. Where is propylene glycol found? Propylene glycol is used as a softening agent, preservative, humectants, and solvent in cosmetics, fragrances, topical medications, soaps and cleansers, hair care products, and deodorants. Propylene glycol is also found in oral treatments as well as many foods. It is also added during the manufacture of many industrial fluids, such as solvents, thinners, antifreeze, other de-icing fluids, desiccants, brake fluids, and polyester resins. How can you avoid contact with propylene glycol? Avoid products that list any of the following names in the ingredients: • Propylene glycol • 1,2-Dihydroxypropane • CASRN: 57-55-6 • Methylethyl glycol • 1,2-Propanediol • 2-Hydroxypropanol • Isopropylene glycol What are some products that may contain propylene glycol? Antiperspirants and Deodorants: • Old Spice High Endurance • Meguiars Vinyl/Rubber Cleaner/Condition • Adidas 24 Hour Deodorant Control Antiperspirant & Deodorant • Pennzoil Roadside Fix A Flat Tire Sealant & • Adidas 24 Hour Fragrance Clear Stick • Old Spice High Endurance Deodorant Flat Preventative Deodorant • Old Spice Red Zone Clear Gel • Rain-X De-Icer (Aerosol) • Adidas Action 3 Tech F • Old Spice Red Zone Deodorant Stick • Slime
  • Lna 2006 Profiles J.Qxp

    Lna 2006 Profiles J.Qxp

    1 | Advertising Age | June 26, 2006 SpecialSpecial ReportReport:100 Profiles LEADING NATIONAL ADVERTISERSSupplement SUPPLEMENT June 26, 2006 100 LEADING NATIONAL ADVERTISERS Profiles of the top 100 U.S. marketers in this 51st annual ranking INSIDE TOP 100 RANKING COMPANY PROFILES SPONSORED BY The nation’s leading marketers Lead marketing personnel, ranked by U.S. advertising brands, agencies, agency expenditures for 2005. contacts, as well as advertising Includes data from TNS Media spending by media and brand, Intelligence and Ad Age’s sales, earnings and more for proprietary estimates of the country’s 100 largest unmeasured spending. PAGE 8 advertisers PAGE 10 This document, and information contained therein, is the copyrighted property of Crain Communications Inc. and The Ad Age Group (© Copyright 2006) and is for your personal, non-commercial use only. You may not reproduce, display on a website, distribute, sell or republish this document, or information contained therein, without prior written consent of The Ad Age Group. Are proud to connect you with the leading CMOs See all the interviews at adage.com/point LAUNCHING JUNE 28 © 2006 Crain Communications Inc. www.adage.com 3 | Advertising Age | June 26, 2006 Special Report 100 LEADING NATIONAL ADVERTISERS SUPPLEMENT ABOUT THIS PROFILE EDITION THE 51ST ANNUAL 100 Leading National the Top 100 ($40.13 billion) and for all measured spending in 18 national media, Advertisers Report crowned acquisition- advertisers ($122.79 billion) in the U.S. Yellow Pages Association contributed ladened Procter & Gamble Co. as the top U.S. ad spending by ad category: This spending in Yellow Pages and TNS Marx leader, passing previous kingpen General chart (Page 6) breaks out 18 measured Promotion Intelligence provided free- Motors Corp.
  • Lifescan Ethicon

    Lifescan Ethicon

    LouiseLouise MehrotraMehrotra ViceVice PresidentPresident InvestorInvestor RelationsRelations ““SafeSafe HarborHarbor”” StatementStatement This presentation may contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company’s expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2006. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from the Company. The Company does not undertake to update any forward-looking statements as a result of new information or future events or developments. WilliamWilliam C.C. WeldonWeldon ChairmanChairman ofof thethe BoardBoard && ChiefChief ExecutiveExecutive OfficerOfficer TodayToday’’ss AgendaAgenda
  • Annual Report

    Annual Report

    ANNUAL REPORT 2019 MARCH 2020 To Our Shareholders Alex Gorsky Chairman and Chief Executive Officer By just about every measure, Johnson & These are some of the many financial and Johnson’s 133rd year was extraordinary. strategic achievements that were made possible by the commitment of our more than • We delivered strong operational revenue and 132,000 Johnson & Johnson colleagues, who adjusted operational earnings growth* that passionately lead the way in improving the health exceeded the financial performance goals we and well-being of people around the world. set for the Company at the start of 2019. • We again made record investments in research and development (R&D)—more than $11 billion across our Pharmaceutical, Medical Devices Propelled by our people, products, and and Consumer businesses—as we maintained a purpose, we look forward to the future relentless pursuit of innovation to develop vital with great confidence and optimism scientific breakthroughs. as we remain committed to leading • We proudly launched new transformational across the spectrum of healthcare. medicines for untreated and treatment-resistant diseases, while gaining approvals for new uses of many of our medicines already in the market. Through proactive leadership across our enterprise, we navigated a constant surge • We deployed approximately $7 billion, of unique and complex challenges, spanning primarily in transactions that fortify our dynamic global issues, shifting political commitment to digital surgery for a more climates, industry and competitive headwinds, personalized and elevated standard of and an ongoing litigious environment. healthcare, and that enhance our position in consumer skin health. As we have experienced for 133 years, we • And our teams around the world continued can be sure that 2020 will present a new set of working to address pressing public health opportunities and challenges.
  • Palm Oil Shopping Guide: Current Best Choices

    Palm Oil Shopping Guide: Current Best Choices

    FOOD Brand Names of FOOD Brand Names of FOOD Brand Names of FOOD Brand Names of FOOD Brand Names of Make a Difference RSPO Members RSPO Members RSPO Members RSPO Members RSPO Members for Wild 3 Musketeers Cinnamon Toast Crunch Honey Maid Grahams Mothers Cookies Splenda Orangutans Act II Coffee Mate Hot Pockets Mountain High Yogurt Starburst Adam's PB Country Crock Hungry Jack Muffin Mam Pastries Stouffers Almond Joy Country Time Hunt's Muir Glen Trident Gum BOYCOTTING PALM Altoids Crisco International Delight Nabisco Sun Chips OIL IS NOT THE Arnott's Biscuits Crunch and Munch Jenny Craig Meals Nature Valley SuperMoist Cake Mixes SOLUTION… Aunt Jemima Foods Dean's Dips Jeno's Pizza Near East Sweet Rewards Bars Austin Brand Crackers Doritos Jif PB Nerds Sweet Tarts Supporting Baby Ruth Dove Chocolates Jiffy Pop Nesquik Swiss Miss companies that are Bac Os Dreyer's Jolly Ranchers Nestle Products Tombstone Pizza members of the Baker's Chocolate Edy's Justin's NutButter Nutter Butter Cookies Tostitos RSPO (Roundtable on Balance Bars Egg Beaters Justin's PB Cups Old El Paso Total Cereal Sustainable Palm Oil) Banquet Meals Endangered Species Choc. Keebler Cookies Oreo Cookies Totino's Pizza is the most Barilla Famous Amos Cookies Keebler Crackers Orville Redenbacher's Trix Cereal responsible solution. BelVita Fiber One Products Kellogg's Products Pam Tuna Helper Ben & Jerry's Ice Cream Fleischmann's Kid Cuisine Parent's Choice Twix Bertolli Frito Lay Kit Kat Parkay Twizzlers For more information Betty Crocker products Folgers Kix Cereal Pasta
  • Over-The-Counter (Otc) Items Benefit

    Over-The-Counter (Otc) Items Benefit

    YOUR 2019 � OVER-THE-COUNTER (OTC) � ITEMS BENEFIT � WellCare proudly serves the Georgia Medicaid and PeachCare for Kids® members enrolled in the Georgia Families® program and women enrolled in the Planning for Healthy Babies® program. GA9CADOTC15578E_0000 � OVER-THE-COUNTER ITEMS BENEFIT Save with Your OTC Benefit Did you know that your OTC benefit can save you money? It can also help you and your family stay healthy. You get this extra benefit at no cost to you. With the OTC benefit, you can choose up to $12 in health and wellness items each month like: • Medicines to help with allergies, fever and heartburn • Cough and cold medicines • Toothbrushes, toothpaste and floss • First aid items • Sunblock • Vitamins You have a long list of more than 200 items to choose from. It is also easy for you to get them. Look over the list on the next few pages. When you make your choices, get the item numbers ready and give us a call. You can call us toll-free. Call us toll-free. Customer Service: 1-866-231-1821 (TTY: 711) We’re here for you Monday–Friday, 7 a.m. to 7 p.m Eastern. www.wellcare.com/Georgia | 1 � OVER-THE-COUNTER ITEMS BENEFIT Remember Use your OTC benefit every month! If you do not use it one month, it does not roll over to the next month. It’s easy to use: If you have a computer or smartphone, log in to our website. Go to www.wellcare.com/Georgia. (Log in with your username and password if you have one.
  • 2016 Annual Report

    2016 Annual Report

    ANNUAL REPORT 2016 MARCH 2017 TO OUR SHAREHOLDERS ALEX GORSKY Chairman and Chief Executive Officer I’ve worked in the health care industry for Rather, true innovations are the result of WE ARE UNITED nearly 30 years. It’s been both an honor and collaboration. And that collaboration is AND INSPIRED a privilege to work for Johnson & Johnson, driven by a diversity of ideas, individuals BY OUR CREDO, a company that touches the lives of over and disciplines – working together toward WHICH RINGS a billion people every day, around the a common goal. AS TRUE TODAY world. As I look at today’s health care AS IT DID WHEN landscape, it’s incredibly clear that the Today, more than ever, the world needs IT WAS WRITTEN pace of change has never been greater, leaders who are committed to working MORE THAN 70 or frankly, more exciting. together to help bring improved health YEARS AGO. and wellness to every person in every Today’s rapid change brings both corner of the globe. As the world’s largest opportunities and risks for any company and most broadly based health care in health care, and we are prepared company, we are uniquely positioned to help to address both. There are significant transform global health care; to shine a light challenges to overcome, but the tools, the on the most important issues we are facing; insights, the technologies, the innovations to collaborate across boundaries and – both evolutions and revolutions – all borders; to uncover scientific insights and combine to make today one of the most ideas; and to dedicate resources towards promising times for human health and for creating tomorrow’s breakthroughs.
  • Johnson & Johnson

    Johnson & Johnson

    Johnson & Johnson - Presenters Alyssa McCulla Anthony Esposito Renee Daggett • Current Role: Asst. Brand • Current Role: Asst. Brand • Current Role: Asst. Brand Manager, Allergy Manager, Allergy Manager, Comp Skin Consumer Promotions Professional • School: Drexel, ‘14 • School: Penn State, ’15 • School: Villanova, ’15 • Major: Communications • Major: Marketing • Major: Marketing/Business Analytics • Experience: • Experience: • JOHNSON’S® Baby, • Marketing co-op, • Experience: innovation JOHNSON’S® Baby • Marketing co-op, • Walmart team – • BENADRYL® Brand, RoC and AVEENO® analyst & shopper forecasting, CP/TP GFO • Three undergrad co- ops, Marketing & PR The #1 Health Care company in the world Decentralized management of companies in three sectors: Medical Devices & Consumer Pharmaceuticals Diagnostics Family in diverse health care business: – Pharmaceuticals – Biotechnology – Contact lenses – Over-the-counter drugs – Consumer packaged goods 265 operating companies in more than 60 countries, employing about 126,500 people Johnson & Johnson Consumer Segment 2015 Sales: $13.5 billion a science-based approach to growth connecting clinically proven efficacy with consumer insights career opportunities to work with some of the world’s most visible and respected brands Lori Kumar, Ph.D. (seen here with daughter Aparna) led the development of LISTERINE® WHITENING® Quick Dissolving Strips Johnson & Johnson Pharmaceuticals Segment 2015 Sales: $31.4 billion We are directly addressing the critical needs of patients around the world Major therapeutic
  • 2012 Citizenship & Sustainability Report

    2012 Citizenship & Sustainability Report

    2 012 Citizenship & Sustainability Report Contents About this Report ......................3 Environmental Impacts ................. 26 Culture of Health Program Global Reporting Initiative (GRI) ........3 Environmental, Health and Safety Provision and Innovation ........... 50 Feedback and Further Information .......3 Management Approach............... 26 Employee Health Goals .............. 50 Goal Setting ....................... 26 Lifestyle and Population Health ...... 51 Letter from the Chairman Organizational Responsibility .... 26 Mental Well-Being .................... 52 and Chief Executive Officer ..........4 Management Systems and Workplace Health Protection ........ 52 Successes & Challenges ..............6 Standards ........................ 27 Globally Harmonized Training ............................. 27 Health Policies .................... 52 Company Profile ........................9 Environmental Compliance ........... 27 Health Outcomes and Impacts ...... 53 Our Brands ................................9 Climate Change ....................... 27 Anti-Counterfeiting ...................... 53 Operational Structure ....................9 Climate Policy Initiatives ......... 27 Significant Changes During the Workplace Health and Safety .......... 53 Facility CO2 Emissions ........... 28 Reporting Period ..................... 10 Contractors ............................ 55 Transportation-Related Fleet Safety ........................... 55 Governance & External CO2 Emissions .................. 31 Commitments ........................